Double transplant strategy aims to keep blood cancer at bay longer
NCT ID NCT01241708
Summary
This study tested whether adding the medication bortezomib to the second of two stem cell transplants helps people with multiple myeloma stay in remission longer. It involved 148 adults who received a first transplant with the standard drug melphalan, followed by a second transplant combining melphalan with bortezomib. The goal was to see if this two-step approach better controls the cancer and delays its return.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center @ Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.